Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Systemic Lupus Erythematosus Clinical Trials

51 recruiting trials for Systemic Lupus Erythematosus. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
51
Total Trials
51
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04751396

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for...

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1251 location
RECRUITINGNCT06379646

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 61 location
RECRUITINGPhase 1NCT07371468

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a...

Sponsor: GlaxoSmithKlineEnrolling: 543 locations
RECRUITINGNCT07180537

Creating Health Course Study for People With Rheumatological Conditions

The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological...

Sponsor: Terry L. WahlsEnrolling: 2001 location
RECRUITINGNCT07000916

Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or...

Sponsor: Université Catholique de LouvainEnrolling: 10001 location
RECRUITINGPhase 2NCT06570798

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis...

Sponsor: AmgenEnrolling: 22020 locations
RECRUITINGPhase 1NCT06340750

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus...

Sponsor: Luminary TherapeuticsEnrolling: 181 location
RECRUITINGNCT05698173

Systemic Lupus Erythematosus and Accelerated Aging

The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.

Sponsor: University Hospital, BordeauxEnrolling: 751 location
RECRUITINGNCT07005479

Long-Term Outcomes in SLE at Peking University People's Hospital

This study aims to prospectively follow patients diagnosed with Systemic Lupus Erythematosus (SLE) at Peking University People's Hospital, assessing long-term outcomes such as...

Sponsor: Peking University People's HospitalEnrolling: 10001 location
RECRUITINGNCT06462768

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage...

Sponsor: CHU de ReimsEnrolling: 2601 location
RECRUITINGPhase 4NCT05559671

Safety of the Herpes Zoster Subunit Vaccine in Lupus

This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate...

Sponsor: NYU Langone HealthEnrolling: 2242 locations
RECRUITINGPhase 1NCT06941129

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 121 location
RECRUITINGPhase 1NCT06465147

REACT-01: Reversing Autoimmunity Through Cell Therapy

This is a phase 1, open-label, non-randomized study enrolling pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to...

Sponsor: Seattle Children's HospitalEnrolling: 121 location
RECRUITINGPhase 2NCT05029336

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose...

Sponsor: Stephan Grupp MD PhDEnrolling: 201 location
RECRUITINGPhase 1NCT06984341

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in...

The purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis...

Sponsor: Genentech, Inc.Enrolling: 1621 location
RECRUITINGNCT07000110

Anifrolumab Malignancy and Serious Infections Study

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive...

Sponsor: AstraZenecaEnrolling: 31954 locations
RECRUITINGNCT06365359

Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique

Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of...

Sponsor: University Hospital Center of MartiniqueEnrolling: 2001 location
RECRUITINGPhase 2NCT05440422

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) -...

Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke....

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Enrolling: 451 location
RECRUITINGNCT06921239

HLA Antibodies in Systemic Lupus Erythematosus

Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 301 location
RECRUITINGNCT06458075

Intervention to Improve Communication and Medication Adherence in Lupus

CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is...

Sponsor: Duke UniversityEnrolling: 4801 location
RECRUITINGPhase 1NCT06576271

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and...

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE...

Sponsor: GlaxoSmithKlineEnrolling: 14220 locations
RECRUITINGPhase 1NCT07403097

Study of CD19 CAR-T Therapy for Refractory SLE

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 181 location
RECRUITINGPhase 1 / Phase 2NCT06347718

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered...

Sponsor: Miltenyi Biomedicine GmbHEnrolling: 241 location
RECRUITINGNCT06795893

The Anifrolumab PRIM Program

Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program

Sponsor: AstraZenecaEnrolling: 2401 location
RECRUITINGNCT06659029

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the...

Sponsor: AstraZenecaEnrolling: 4421 location
RECRUITINGPhase 4NCT05916781

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

The goal of this clinical trial is to determine whether mycophenolate mofetil(MMF) combined with tacrolimus(TAC) can maintain remission in patients with lupus nephritis (LN) who...

Sponsor: Chinese SLE Treatment And Research GroupEnrolling: 2201 location
RECRUITINGPhase 3NCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With...

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib...

Sponsor: AbbVieEnrolling: 100020 locations
RECRUITINGPhase 1 / Phase 2NCT06106893

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of CD19 Universal CAR-γδT cells in active severe systemic lupus erythematosus.

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 151 location
RECRUITINGPhase 3NCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus...

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the...

Sponsor: Novartis PharmaceuticalsEnrolling: 55020 locations
RECRUITINGPhase 1NCT05835986

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in...

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus...

Sponsor: Hoffmann-La RocheEnrolling: 7020 locations
RECRUITINGPhase 1NCT06657703

Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary...

Sponsor: HC Biopharma Inc.Enrolling: 383 locations
RECRUITINGPhase 1 / Phase 2NCT06106906

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of CD19 CAR-T in active systemic lupus erythematosus.

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 151 location
RECRUITINGPhase 1NCT06857214

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

This study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 541 location
RECRUITINGPhase 1NCT07011043

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be...

Sponsor: Climb Bio, Inc.Enrolling: 3018 locations
RECRUITINGPhase 4NCT06411249

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus...

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody...

Sponsor: GlaxoSmithKlineEnrolling: 35020 locations
RECRUITINGPhase 1NCT06400537

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 252 locations
RECRUITINGNCT06361745

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). Secondary purpose: To evaluate the...

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 101 location
RECRUITINGNCT03138941

Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether...

Sponsor: Monash UniversityEnrolling: 500020 locations
RECRUITINGPhase 1NCT07318259

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 181 location
RECRUITINGEarly Phase 1NCT06711146

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active...

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus

Sponsor: Zhejiang UniversityEnrolling: 361 location
RECRUITINGPhase 1 / Phase 2NCT06350110

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002...

Sponsor: Essen BiotechEnrolling: 751 location
RECRUITINGNCT05007340

ILD-SARDs Registry and Biorepository

A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and...

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 2521 location
RECRUITINGPhase 1NCT05869955

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases...

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases...

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 27020 locations
RECRUITINGNCT06544343

Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy

Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the...

Sponsor: University Of PerugiaEnrolling: 1901 location
RECRUITINGPhase 1NCT03816345

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in...

Sponsor: National Cancer Institute (NCI)Enrolling: 30020 locations
RECRUITINGNCT05927688

Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or...

Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 3521 location
RECRUITINGPhase 2 / Phase 3NCT06618573

Safety of Administering Isoniazid to SLE Patients to Prevent TB

Systemic Lupus Erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by heterogeneity, multisystem involvement, and production of multiple...

Sponsor: Universitas PadjadjaranEnrolling: 601 location
RECRUITINGNCT04402086

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Sponsor: Yale UniversityEnrolling: 50001 location
RECRUITINGPhase 1 / Phase 2NCT06428188

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both...

Sponsor: Essen BiotechEnrolling: 601 location
RECRUITINGNCT03276923

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to...

Sponsor: Duke UniversityEnrolling: 10001 location

Showing 50 of 51 trials.Search all Systemic Lupus Erythematosus trials

Frequently Asked Questions

There are currently 51 clinical trials for Systemic Lupus Erythematosus, with 51 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Systemic Lupus Erythematosus, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Systemic Lupus Erythematosus, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.